Alcohol and the liver

Current Opinion in Gastroenterology

Volumn 24, Issue 3, 2008, Pages 328-338

  Reuben, Adrian ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MSC 290 ^*  (United States)

Author keywords

Alcoholic liver disease; Biomarkers; Cytochrome P450 2E1; Liver transplantation; Oxidative stress; Signaling pathways

Indexed keywords

2 HYDROXY 4 METHOXYBENZOIC ACID; ACETYLCYSTEINE; ADIPONECTIN; ALCOHOL; AMINO ACID DERIVATIVE; ANTIOXIDANT; ATORVASTATIN; BENZOIC ACID DERIVATIVE; BETAINE; CYTOCHROME P450 2E1; DITERPENOID; ELLAGIC ACID; EPIGALLOCATECHIN GALLATE; FLAVONOID; GINKGO BILOBA EXTRACT; HEMIDESMUS INDICUS EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINERAL; OCIMUM BASILICUM EXTRACT; PARACETAMOL; PLANT EXTRACT; PLATYCODON GRANDIFLORUM EXTRACT; POLYPHENOL DERIVATIVE; PROTEOGLYCAN; QUERCETIN; RESVERATROL; STEROID; TERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; ALCOHOLISM; ANALGESIC AGENT ABUSE; BASIL; CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC PROCEDURE; EPIDEMIOLOGICAL DATA; FENUGREEK; GENETIC POLYMORPHISM; GENETICS; HUMAN; LIVER; LIVER TOXICITY; LIVER TRANSPLANTATION; MAIZE; MITOCHONDRIAL TOXICITY; MUSHROOM; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; RED WINE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION;

ALCOHOL DRINKING; BIOLOGICAL MARKERS; COMORBIDITY; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER TRANSPLANTATION; OXIDATIVE STRESS; SUBSTANCE ABUSE DETECTION;

EID: 42249084883     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282fbceca     Document Type: Review

References (182)

1. Henderson JS, Joyce RA, Halls GR, et al. Chemical and archeological evidence for the earliest cacao beverages. Proc Natl Acad Sci 2007; 104:18937-18940. The earliest appearance of chocolate drinks is pushed back 500 years.
2. Bosetti C, Levi F, Lucchini F, et al. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46:827-839. The most current compilation of age-standardized cirrhosis mortality rates worldwide, 1980-2002.
3. Ramstedt M. Population drinking and liver cirrhosis mortality: is there a link in eastern Europe? Addiction 2007; 102:1212-1223.
4. Lachenmeier DW, Rehm J, Gmel G. Surrogate alcohol: what do we know and where do we go? Alcohol Clin Exp Res 2007; 31:1613-1624. Yet another lifestyle scourge.
5. Rehm J, Sulkowska U, Mańczuk M, et al. Alcohol accounts for a high proportion of premature mortality in central and eastern Europe. Int J Epidemiol 2007; 36:458-467.
6. Leyland AH, Dundas R, McLoone P, Boddy FA. Cause-specific inequalities in mortality in Scotland: two decades of change. A population-based study. BMC Public Health 2007; 7:172.
7. Seitz HK, Stickel F. Alcoholic liver disease in the elderly. Clin Geriatr Med 2007; 23:905-921. An important but frequently overlooked trend.
8. Schneider M, Norman R, Parry C, et al. Estimating the burden of disease attributable to alcohol use in South Africa in 2000. S Afr Med J 2007; 97:664-672.
9. Najman JM, Williams GM, Room R. Increasing socioeconomic inequalities in male cirrhosis of the liver mortality: Australia 1981-2002. Drug Alcohol Rev 2007; 26:273-278.
10. Menvielle G, Kunst AE, Stirbu I, et al. Socioeconomic inequalities in alcohol related cancer mortality among men: to what extent do they differ between Western European populations? Int J Cancer 2007; 121:649-655.
11. Polednak AP. Secular trend in US black-white disparities in selected alcohol-related cancer incidence rates. Alcohol Alcohol 2007; 42:125-130.
12. Haukeland JW, Lorgen I, Schreiner LT, et al. Incidence rates and causes of cirrhosis in a Norwegian population. Scand. J Gastroenterol 2007; 12:1-8.
13. Stewart SH, Connors GJ. Ethnicity, alcohol drinking and changes in transaminase activity among heavy drinkers. J Natl Med Assoc 2007;99:564-569.
14. Kerr-Corrêa F, Igami TZ, Hiroce V, Tucci AM. Patterns of alcohol use between genders: a cross-cultural evaluation. J Affect Disord 2007; 102:265-275. Men and women drink alcohol differently.
15. Marugame T, Yamamoto S, Yoshimi I, et al. Patterns of alcohol drinking and all-cause mortality: results from a large-scale population-based cohort study in Japan. Am J Epidemiol 2007; 165:1039-1046. Brief respites from alcohol binges may be 'relatively healthy'.
16. Diaz-Granados JL, Graham DL. The effects of continuous and intermittent ethanol exposure in adolescence on the aversive properties of ethanol during adulthood. Alcohol Clin Exp Res 2007; 31:2020-2027.
17. Tsukamoto H. Conceptual importance of identifying alcoholic liver disease as a lifestyle disease. J Gastroenterol 2007; 42:603-609. Comprehensive overview of ALD that reaches far beyond the concept of alcohol as a hepatotoxin.
18. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007; 27:44-54. Comprehensive review of all facets of genetic predispositions to ALD and non-alcoholic fatty liver disease.
19. Yang M, Tsuang J, Wan Y-JY. A haplotype analysis of CYP2E1 polymorphisms in relation to alcoholic phenotypes in Mexican Americans. Alcohol Clin Exp Res 2007; 31:1991-2000.
20. Auguet T, Vida F, López-Dupla M, et al. A study on the TNF-alpha system in Caucasian Spanish patients with alcoholic liver disease. Drug Alcohol Depend 2008; 92:91-99.
21. Robinson G, Narasimhan S, Weatherall M, Beasley R. Hemochromatosis gene mutations, liver function tests and iron status in alcohol-dependent patients admitted for detoxification. J Gastroenterol Hepatol 2007; 22:852-854. Dispels the notion that there is a genetic link between alcoholism and hemochromatosis.
22. Cichoz-Lach H, Partycka J, Nesina I, et al. Alcohol dehydrogenase and aldehyde dehydrogenase gene polymorphism in alcohol liver cirrhosis and alcohol chronic pancreatitis among Polish individuals. Scan J Gastroenterol 2007; 42:493-498.
23. Moore S, Montane-Jaime K, Shafe S, et al. Association of ALDH1 promoter polymorphisms with alcohol-related phenotypes in Trinidad and Tobago. J Stud Alcohol Drugs 2007; 68:192-196.
24. Ehlers CL, Montane-Jaime K, Moore S, et al. Association of the ADHIB*3 allele with alcohol-related phenotypes in Trinidad. Alcohol Clin Exp Res 2007; 31:216-220.
25. Quintanilla ME, Tampler L, Sapag A, et al. Sex differences, alcohol dehydrogenase, acetaldehyde burst, and aversion to ethanol in the rat: a systems perspective. Am J Physiol Endocrinol Metab 2007; 29:E531-E537.
26. Cichoz-Loch H, Partycka J, Nesina I, et al. Genetic polymorphism of alcohol dehydrogenase 3 in digestive tract alcohol damage. Hepatogastroenterology 2007; 54:216-220.
27. ••].
28. ••].
29. ••].
30. ••].
31. ••] are excellent reviews of the genetics of alcohol and acetaldehyde metabolism.
32. Tseng YM, Hu BW, Tsai SM, et al. Distribution of alcohol-metabolizing enzyme genotypes in trauma patients with excessive alcohol consumption in the emergency department. Clin Biochem 2007; 40:370-376.
33. Tseng YM, Jin YR, Chen IJ, et al. Roles of the genetic variation of alcohol-metabolizing enzymes on biomarkers in trauma patients with excessive alcohol intake at emergency department. Clin Chim Acta 2008; 389:14-18.
34. Matsumoto A, Ichiba M, Horita M, et al. Lack of aldehyde dehydrogenase ameliorates oxidative stress induced by single-dose ethanol administration in mouse liver. Alcohol 2007; 41:57-59.
35. Ocaranza P, Quintanilla ME, Tampier L, et al. Gene therapy reduces ethanol intake in an animal model of alcohol dependence. Alcohol Clin Exp Res 2008; 32:52-57. Antisense gene therapy offers short-term cure for alcoholic rats.
36. Hesse M, Thiesen H. The CAGE as a measure of hazardous drinking in the homeless. Am J Addict 2007; 16:475-478.
37. Kamal A, Cheung R. Positive CAGE screen correlates with cirrhosis in veterans with chronic hepatitis C. Dig Dis Sci 2007; 52:2564-2569.
38. Au DH, Kivlahan Dr, Bryson CL, et al. Alcohol screening scores and risk of hospitalization for GI conditions in men. Alcohol Clin Exp Res 2007; 31:443-451.
39. Agabio R, Marras P, Gessa GL, Carpiniello B. Alcohol use disorders, and at-risk drinking in patients affected by a mood disorder, in Cagliari Italy: sensitivity and specificity of different questionnaires. Alcohol Alcohol 2007; 42:575-581.
40. Bradley KA, DeBenedetti AF, Volk RJ, et al. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res 2007; 31:1208-1217.
41. Graham A, Goss C, Xu S, et al. Effect of using different modes to administer the AUDIT-C on identification of hazardous drinking and acquiescence of trial participation among injured patients. Alcohol Alcohol 2007; 42:423-429.
42. Seale JP, Boltri JM, Shellenberger S. Primary care validation of a single screening question for drinkers. J Stud Alcohol 2006; 67:778-784.
43. Li T-K, Hewitt BG, Grant BF. Is there a future for quantifying drinking in the diagnosis, treatment, and prevention of alcohol use disorders? Alcohol Alcohol 2007; 41:57-63.
44. ••].
45. ••] are two outstanding reviews of alcohol excess consumption biomarkers.
46. Bergström JP, Helander A. Influence of alcohol use, ethnicity, age, gender, BMI and smoking on the serum transferrin glycoform pattern: Implications for use of carbohydrate-deficient transferrin (CDT) as alcohol biomarker. Clin Chim Acta 2008; 388:59-67.
47. Begrström JP, Helander A. HPLC evaluation of clinical and pharmacological factors reported to cause false-positive carbohydrate-deficient transferrin (CDT) levels. Clin Chim Acta 2008; 389:164-166.
48. Schellenberg F, Girre C, Nalpas B, et al. Analytical evaluation of a new capillary electrophoresis method for carbohydrate-deficient transferrin measurement. Clin Chim Acta 2007; 382:48-53.
49. Jeppsson J-O, Arndt T, Schellenberg F, et al. Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method. Clin Chem Lab Med 2007; 45:558-562.
50. Chrostek L, Cylwik B, Korcz W, et al. Serum free sialic acid as a marker of alcohol abuse. Alcohol Clin Exp Res 2007; 31:996-1001.
51. Gong M, Garige M, Hirsch K, Lakshman MR. Liver Galβ1,4G1cNAc α2, 6-sialyltransferase is down-regulated in human alcoholics: possible cause for the appearance of asialoconjugates. Metab Clin Exp 2007; 56:1241-1247.
52. Beck O, Stephanson N, Böttcher M, et al. Biomarkers to disclose recent intake of alcohol: potential of 5-hydroxytryptophol glucuronide testing using new direct UPLC-tandem MS and ELISA methods. Alcohol Alcohol 2007; 42:321-325.
53. Wojcik MH, Hawthorne JS. Sensitivity of commercial ethyl glucuronide (EtG) testing in screening for alcohol abstinence. Alcohol Alcohol 2007; 42:317-320.
54. Sarkola T, Dahl H, Eriksson CJP, Helander A. Urinary ethyl glucuronide and 5-hydroxytryptophol levels during repeated ethanol ingestion in healthy human subjects. Alcohol Alcohol 2003; 38:347-351.
55. Morini L, Politi L, Zucchella A, Polettini A. Ethylglucuronide and ethyl sulphate determination in serum by liquid chromatography-electrospray tandem mass spectrometry. Clin Chim Acta 2007; 376:213-219.
56. Dierkes J, Wolfersdorf M, Borucki K, et al. Determination of glucuronidated 5-hydroxtryptophol (GTOL), a marker of recent alcohol intake, by ELISA technique. Clin Biochem 2007; 40:128-131.
57. Helander A, Olssom I, Dahl H. Postcollection synthesis of ethyl glucuronide by bacteria in urine may cause false identification of alcohol consumption. Clin Chem 2007; 53:1855-1857. Urine infection can give both false-positive (as here) and false-negative results for EtG, but not for EtS.
58. Costantino A, Digregorio EJ, Korn W, et al. The effect of the use of mouthwash on ethylglucuronide concentrations in urine. J Anal Toxicol 2006; 30:659-662.
59. Erim Y, Böttcher M, Dahmen U, et al. Urinary ethyl glucuronide testing detects alcohol consumption in alcoholic liver disease patients awaiting liver transplantation. Liver Transpl 2007; 13:757-761.
60. Appenzeller BM, Agirman R, Neuberg P, et al. Segmental determination of ethyl glucuronide in hair: A pilot study. Forensic Sci Int 2007; 173:87-92.
61. Hoiseth G, Bernard JP, Karinen R, et al. A pharmacokinetic study of ethyl glucuronide in blood and urine: applications to forensic toxicology. Forensic Sci Int 2007; 172:119-124.
62. Pragst F, Balikova MA. State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta 2006; 370:17-49.
63. Hartmann S, Aradottir S, Graf M, et al. Phosphatidylethanol as a sensitive and specific biomarker: comparison with gamma-glutamyl transpeptidase, mean corpuscular volume and carbohydrate-deficient transferrin. Addict Biol 2007; 12:81-84. A relatively new blood biomarker for excess alcohol drinking, with 2- to 3-week durability following abstinence.
64. •].
65. •].
66. •] are three reviews on oxidative stress, including descriptions of the role of CYP2E1 in generating reactive oxygen species.
67. Konishi M, Ishii H. Role of microsomal enzymes in development of alcoholic liver diseases. J Gastroenterol Hepatol 2007; 22 (Suppl 1):S7-S10. A review of ethanol-induced upregulation of CYP2E1 in the generation of reactive oxygen species.
68. Kaplowitz N, Than TA, Shinohara M, Ji C. Endoplasmic reticulum stress and liver injury. Semin Liv Dis 2007; 27:367-377. Review of the physiologically normal 'unfolded protein response' in the endoplasmic reticulum, and its pathological upregulation, which is now known to occur in many liver diseases.
69. Niemelä O. Acetaldehyde adducts in circulation. Novartis Found Symp 2007; 285:183-192; discussion 193-197. Review of the formation and systemic response to acetaldehyde-protein adducts, which can cause widespread organ damage.
70. Mantena SK, King AL, Andringa KK, et al. Novel interaction of mitochondria and reactive oxygen/nitrogen species in alcohol mediated liver disease. World J Gastroenterol 2007; 13:4967-4973. Review of posttranslational changes in mitochondrial proteins, caused by reactive oxygen and nitrogen radicals induced by excessive alcohol.
71. •].
72. •] review the function of the proteasome - nonlysosomal enzymes that are responsible for the degradation of intracellular proteins - in the pathogenesis of ALD.
73. Nitti M, Pronzato MA, Marinari UM, Domenicotti C. PKC signaling in oxidative hepatic damage. Mol Aspects Med 2008; 29:36-42. A review of the role of protein kinase C isoenzymes as 'stress sensors' in the cellular responses to injury.
74. Enomoto N, Takei Y, Yamashina S, et al. Anti-inflammatory strategies in alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22 (Suppl 1):S59-S61. Two reviews of the biology of Kupffer cell-derived TNF-a in alcohol hepatitis.
75. Thakur V, McMullen MR, Pritchard MT, Nagy LE. Regulation of macrophage activation in alcoholic liver disease. J Gastronterol Hepatol 2007; 22 (Suppl 1):S53-S56. Two reviews of the biology of Kupffer cell-derived TNF-α in alcohol hepatitis.
76. Mandrekar P. Signaling mechanisms in alcoholic liver injury: role of transcription factors, kinases and heat shock proteins. World J Gastroenterol 2007; 13:4979-4985. Review of the complex topic of Toll-like receptor activation and alterations in transcription factors and other downstream events in hepatocytes and nonparenchymal cells in the liver in alcoholic injury.
77. •].
78. •] are two reviews of cell death and replication in the setting of ethanol hepatotoxicity.
79. Donohue TM Jr. Alcohol-induced steatosis in liver cells. World J Gastroenterol 2007; 13:4974-4978. An update on the mechanisms leading to alcoholic fatty liver, focusing on newly described molecular events involving transcription factors, induction of genes of lipid synthesis and downregulation of fatty acid oxidation.
80. Duryee MJ, Klassen LW, Thiele GM. Immunological response in alcoholic liver disease. World J Gastroenterol 2007; 13:4938-4946. Insight into how an immune reaction to modified liver proteins released into the circulation could be involved in the development and/or progression of ALD.
81. Lieber CS, Cao Q, DeCarli LM, et al. Role of medium-chain triglycerides in the alcohol-mediated cytochrome P450 2E1 induction of mitochondria. Alcohol Clin Exp Res 2007; 31:1660-1668. Induction of mitochondrial CYP2E1 by alcohol, with attendant lipid peroxidation and glutathione depletion; effects mitigated by medium-chain triglyceride feeding.
82. Czaja MJ. Cell signaling in oxidative stress-induced liver injury. Semin Liver Dis 2007; 27:378-389. A detailed and densely worded review of the molecular mechanisms by which acute and chronic oxidative stress alters cell signaling to lead to cell death.
83. Sampey BP, Stewart BJ, Peterson DR. Ethanol-induced modulation of hepatocellular extracellular signal-regulated kinase-1/2 activity via 4-hydroxynoneal. J Biol Chem 2007; 282:1925-1937.
84. Balasubramaniyan V, Shukla R, Murugaiyan G, et al. Mouse recombinant leptin protects human hepatoma HepG2 against apoptosis, TNF-alpha response and oxidative stress induced by the hepatotoxin-ethanol. Biochim Biophys Acta 2007; 1770:1136-1144.
85. Yan M, Zhu P, Liu HM, et al. Ethanol induced mitochondria injury and permeability transition pore opening: role of mitochondria in alcoholic liver disease. World J Gastroenterol 2007; 28:2352-2356.
86. Song Z, Zhou Z, Song M, et al. Alcohol-induced S-adenosylhomocysteine accumulation in the liver sensitizes to TNF hepatotoxicity: possible involvement of mitochondrial S-adenosylmethionine transport. Biochem Pharmacol 2007; 74:521-531. Mechanism for mitochondrial SAMe depletion.
87. •].
88. •].
89. •] collectively the potential participation of homocysteine in causing hepatic steatosis by inhibiting adiponectin is suggested.
90. Karaa A, Thompson KJ, McKillop IH, et al. S-adenosyl-L- methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model. Shock; 2007 [Epub ahead of print]. SAMe supplementation reduces steatosis and fibrosis in rats exposed to ethanol and endotoxin.
91. Wang X, Cederbaum AI. Acute ethanol pretreatment increases FAS-mediated liver injury in mice: role of oxidative stress and CYP2E1-dependent and -independent pathways. Free Radic Biol Med 2007; 42:971-984.
92. •].
93. •] show ageing rodents have reduced glutathione reserve and recover poorly from its depletion by alcohol.
94. Gyamfi MA, Damjanov I, French S, Wan Y-JY. The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem Pharmacol 2008; 75:981-995.
95. Nieto N, Rojkind M. Repeated whiskey binges promote liver injury in rats fed a choline-deficient diet. J Hepatol 2007; 46:330-339.
96. Sharma MR, Polavarapu R, Roseman D, et al. Increased severity of alcoholic liver injury in female verses male rats: a microarray analysis. Exp Mol Path 2008; 84:46-58.
97. Park S-H, Choi M-S, Park T. Changes in the hepatic gene expression profile in a rat model of chronic ethanol treatment. Food Chem Toxicol 2008; 46:1378-1388.
98. Pal-Bhadra M, Bhadra U, Jackson DE, et al. Distinct methylation patterns in histone H3 at Lys-4 and Lys-9 correlate with up- & down-regulation of genes by ethanol in hepatocytes. Life Sci 2007; 81:979-987.
99. Bardag-Gorce F, French BA, Joyce M, et al. Histone acetyltransferase p300 modulates gene expression in an epigenetic manner at high blood alcohol levels. Exp Mol Pathol 2007; 82:197-202.
100. -/- mice that do not develop ethanol-induced steatosis. J Hepatol 2007; 46:907-914.
101. McVicker BL, Tuma DJ, Kharbanda KK, et al. Effect of chronic ethanol administration on the in vitro production of proinflammatory cytokines by rat Kupffer cells in the presence of apoptotic cells. Alcohol Clin Exp Res 2007; 31:122-129.
102. Harrison-Findik DD, Klein E, Crist C, et al. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology 2007; 46:1979-1985.
103. Jeong WI, Park O, Gao B. Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 2008; 134:248-258.
104. Elphick DA, Dube AK, McFarlane E, et al. Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am J Gastroenterol 2007; 102:780-788. Nowadays one rarely needs to do a liver biopsy to exclude other causes of decompensation in ALD.
105. Singal AK, Anand BS. Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol 2007; 41:761-772.
106. •].
107. •] are two epidemiological reports of the life-shortening effect of heavy alcohol use in HCV infection in France and the US.
108. •].
109. •].
110. •] indicate potential basic mechanisms for the adverse interaction between alcohol and HCV.
111. Aloman C, Gebring S, WIntermeyer P, et al. Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dentritic cell dysfunction. Gastroenterology 2007; 132:698-708.
112. Cheng DM, Nunes D, Libman H, et al. Impact of hepatitis C on HIV progression in adults with alcohol problems. Alcohol Clin Exp Res 2007; 31:829-836.
113. Gonzalez FJ. The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab Dispos 2007; 35:1-8. Comprehensive review of CYP2E1 biology and role in acetaminophen and other drug hepatotoxicity.
114. Moulakakis KG, Sfyroeras G, Pavlidis P, et al. Hypercoagulable state due to alcohol-paracetamol syndrome producing acute limp ischemia. Vasc Endovasc Surg 2007; 41:362-365.
115. Seifert CF, Anderson DC. Acetaminophen usage patterns and concentrations of glutathione and gamma-glutamyl transferase in alcoholic subjects. Pharmacotherapy 2007; 27:1473-1482.
116. Kuffner EK, Green JL, Bogdan GM, et al. The effect of acetaminophen (four grams a day for three consecutive days) on hepatic tests in alcoholic patients - a multicenter randomized study. BMC Med 2007; 5:13.
117. Heard K, Green JL, Bailey JE, et al. A randomized trial to determine the change in alanine aminotransferase during 10 days of paracetamol (acetaminophen) administration in subjects who consume moderate amounts of alcohol. Aliment Pharmacol Ther 2007; 26:283-290.
118. Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 2007; 11:597-603. Expert opinion of the safety of statins in patients with chronic liver disease (together with the next four references).
119. Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007; 46:1453-1463.
120. Hussaini SH, Farrington EA. Idiosyncratic drug-induce liver injury: an overview. Expert Opin Drug Saf 2007; 6:673-684.
121. Chen YW, Lai HW, Wang TD. Marked elevation of liver transaminases after high-dose fluvastatin unmasks chronic hepatitis C: safety and re-challenge. Acta Neurol Taiwan 2007; 16:163-167.
122. Segarra-Newman M, Parra D, Martin-Cooper EM. Effectiveness and hepatotoxoicty of statins in men seropositive for hepatitis C virus. Pharmacotherapy 2007; 27:845-851.
123. Ito DT, Molina HM, Andriolo A, Borges DR. The combination of atorvastatin and ethanol is not more toxic to rats than the administration of each drug alone. Braz J Med Biol Res 2007; 40:343-348.
124. Elsing C, Placke J, Herrmann T. Alcohol binging causes peliosis hepatis during azathioprine therapy in Crohn's disease. World J Gastroenterol 2007; 13:4646-4648. An unusual drug hepatotoxicity brought on by alcohol binging.
125. Coiro V, Casti A, Jotti GS, et al. Adrenocorticotropic hormone response to physical exercise in abstinent patients. Alcohol Clin Exp Res 2007; 31:901-906.
126. Ahmed A, Saksena S, Sherlock, et al. Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease. Clin Endocrinol (Oxf); 2007 [Epub ahead of print]. Hepatic steroid-metabolizing enzyme upregulation that explains pseudo-Cushing's syndrome in ALD.
127. Sumida KD, Hill JM, Matveyenko AV. Sex differences in hepatic gluconeogenic capacity after chronic alcohol consumption. Clin Med Res 2007; 5:193-202.
128. Fueki Y, Miida T, Wardaningsih E, et al. Regular alcohol consumption improves insulin resistance in healthy Japanese men independent of obesity. Clin Chim Acta 2007; 382:71-76.
129. He L, Marecki JC, Serrero G, Simmen FA, et al. Dose-dependent effects of alcohol on insulin signaling: partial explanation for biphasic alcohol impact on human health. Mol Endocrinol 2007; 21:2541-2550. Reasons why moderate drinking may prevent diabetes whereas heavy drinking causes it.
130. Beulens JW, van den Berg R, Kock FJ, et al. Moderate alcohol consumption and lipoprotein-associated phospholipase A2 activity. Nutr Metab Cardiovasc Dis; 2007 [Epub ahead of print].
131. Khogo Y, Ikuta K, Ohtake T, et al. Iron overload and cofactors with special reference to alcohol, hepatitis C virus infection and steatosis/insulin resistance. World J Gastroenterol 2007; 13:4646-4648.
132. Harrison-Findik DD. Role of alcohol in the regulation of iron metabolism. World J Gastroenterol 2007; 13:4925-4930.
133. Flanagan JM, Peng H, Beutler E. Effects of alcohol consumption on iron metabolism in mice with hemochromatosis mutations. Alcohol Clin Exp Res 2007; 31:138-143.
134. Banan A, Keshavarzian A, Zhang L, et al. NF-kappaB activation as a key mechanism in ethanol-induced disruption of the F-actin cytoskeleton and monolayer barrier integrity in intestinal epithelium. Alcohol 2007; 41:447-460.
135. Tang Y, Ali A, Forsyth CB, et al. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res 2008; 32:355-364.
136. Bhonchal S, Nain CK, Prasad KK, et al. Functional and morphological alterations in small intestine mucosa of chronic alcoholics. J Gastroenterol Hepatol; 2007. Epub ahead of print.
137. •].
138. •] are two examples of false-positive autoantibodies in ALD.
139. Price LA, Thombs B, Chen CL, Milner SM. Liver disease in burn injury: evidence from a national sample of 31 338 adult patients. J Burns Wounds 2007; 7:1-11.
140. O'Brien JM Jr, Lu B, Ali NA, et al. Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients. Crit Care Med 2007; 35:345-350.
141. Peng GS, Yin SJ, Cheng CA, et al. Increased risk of cerebral hemorrhage in Chinese male heavy drinkers with mild liver disorder. Cerebrovasc Dis 2007; 23:309-314.
142. Alexander-Kaufman K, Harper C, Wilce P, Matsumoto I. Cerebellar vermis proteome of chronic alcoholic individuals. Alcohol Clin Exp Res 2007; 31:1286-1296.
143. Kashem MA, James G, Harper C, et al. Differential protein expression in the corpus callosum (splenium) of human alcoholics: a proteomics study. Neurochem Int 2007; 50:450-459.
144. Saravanan N, Nalini N. Antioxidant effect of Hemidesmus indicus on ethanol-induced hepatotoxicity in rats. J Med Food 2007; 10:675-682.
145. Saravanan N, Rajasankar S, Nalini N. Antioxidant effect of 2-hydroxy 4-methoxy benzoic acid on ethanol-induced hepatotoxicity in rats. J Pharm Pharmacol 2007; 59:445-453.
146. Yun JW, Kim YK, Lee BS, et al. Effect of dietary epigallocatechin-3-gallate on cytochrome P450-2E1-dependent alcoholic liver damage: enhancement of fatty acid oxidation. Biosci Biotechnol Biochem 2007; 71:2999-3006.
147. Yao P, Nussler A, Liu L, et al. Quercetin protects human hepatocytes from ethanol-derived oxidative stress by inducing heme oxygenase-1 via the MAPK/Nrf2 pathways. J Hepatol 2007; 64:10-12.
148. Yao P, Li K, Song F, et al. Heme oxygenase-1 upregulated by Ginkgo biloba extract: potential protection against ethanol-induced oxidative liver damage. Food Chem Toxicol 2007; 45:1333-1342.
149. Singha PK, Roy S, Dey S. Protective activity of andrographolide and arabinogalactan proteins from Andrographis paniculata Nees against ethanol-induced toxicity in mice. J Ethnopharmacol 2007; 111:13-21.
150. Devipriya N, Srinivasan M, Sudheer AR, Menon VP. Effect of ellagic acid, a natural polyphenol, on alcohol-induced prooxidant and antioxidant imbalance: a drug dose dependent study. Singapore Med J 2007; 48:311-318.
151. Kaviarasan S, Anuradha CV. Fenugreek (Trigonella foenum graecum) seed polyphenols protect liver from alcohol toxicity: a role on hepatic detoxification system and apoptosis. Pharmazie 2007; 62:299-304.
152. Kasdallah-Grissa A, Mornagui B, Aouani E, et al. Reservatrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci 2007; 80:1033-1039.
153. Kim HK, Kim DS, Cho HY. Protective effects of Platycodi radix on alcohol-induced fatty liver. Biosci Biotechnol Biochem 2007; 71:1550-1552.
154. Chaturvedi R, George S, John A. Preventive and protective effects of wild basil in ethanol-induced liver toxicity in rats. Br J Biomed Sci 2007; 64:10-12.
155. Lu ZM, Tao WY, Zou XL, et al. Protective effects of mycelia of Antrodia camphorate and Armillariella tabescens in submerged culture against ethanol-induced hepatic toxicity in rats. J Ethnopharmacol 2007; 110:160-164.
156. Li HM, Guo P, Hu X, et al. Preparation of corn (Zea mays) peptides and their protective effect against alcohol-induced hepatic injury in NH mice. Biotechnol Appl Biochem 2007; 47:169-174.
157. Ki SH, Choi JH, Kim CW, Kim SG. Combined metadoxine and garlic oil treatment efficaciously abrogates alcoholic steatosis and CYP2E1 induction in rat liver with restoration of AMPK activity. Chem Biol Interact 2007; 169:80-90.
158. Donahue TM Jr, Curry-McCoy TV, Toderos L, et al. L-Buthionine (S,R) sulfoximine depletes hepatic glutathione but protects against ethanol-induced liver injury. Alcohol Clin Exp Res 2007; 31:1053-1060.
159. Purohit V, Abdelmalek MF, Barve S, et al. Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr 2007; 86:14-24.
160. Esfandiari F, You M, Villaneuva JA, et al. S-adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate-deficient diet. Alcohol Clin Exp Res 2007; 31:1231-1239.
161. Kharbanda KK, Mailliard ME, Baldwin CR, et al. Accumulation of proteins bearing atypical isoaspartyl residues in livers of alcohol-fed rats is prevented by betaine administration: effects on protein-L-isoaspartyl methyltransferase activity. J Hepatol 2007; 46:1119-1125.
162. Kharbanda KK, Mailliard ME, Baldwin CR, et al. Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway. J Hepatol 2007; 46:314-321.
163. Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2005; 2:CD003620.
164. Stewart S, Prince M, Bassendine M, et al. A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 2007; 47:277-283. Another failed trial in alcoholic hepatitis, but perhaps not expected to succeed since the therapeutic arm was limited to N-acetylcysteine for 1 week, with added vitamins and minerals only, to compete against steroids.
165. Hamdi H, Bigorgne A, Naveau S, et al. Glucocorticoid-induced leucine zipper: a key protein in the sensitization of monocytes to lipopolysaccharide in alcoholic hepatitis. Hepatology 2007; 46:1986-1992.
166. Forrest EH, Morris AJ, Stewart S, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56:1743-1746. New severity score for alcoholic hepatitis - based on age, white cell count, urea, INR and bilirubin - from Scotland, which looks very promising in usage so far.
167. Louvet A, Naveau S, Abdelnour M, et al. The Lille model: a new tool for therapeutic strategy in patients with sever alcoholic hepatitis treated with steroids. Hepatology 2007; 45:1348-1354.
168. Rincon D, Lo Iacono O, Ripoll C, et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther 2007; 25:841-848.
169. Metsuyama T, Uemura M, Ishikawa M, et al. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2007; 31 (Suppl 1):27S-35S.
170. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study. Lancet 2007; 370:1915-1922. Small trial with large benefit.
171. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence. A randomized controlled trial. JAMA 2007; 298:1641-1651. Large trial with small benefit.
172. Tilg H, Day CP. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007; 4:24-34.
173. Maher JJ. Alcoholic steatohepatitis: management and prognosis. Curr Gastroenterol Rep 2007; 9:39-46.
174. Neuberger J. Public and professional attitudes to transplanting alcoholic patients. Liver Transpl 2007; 13 (Suppl 2):S65-S68.
175. Dimartini A. Natural history of alcohol use disorders in liver transplant patients. Liver Transpl 2007; 13 (Suppl 2):S76-S78.
176. Weinrieb RM, Lucey MR. Treatment of addictive behaviors in liver transplant patients. Liver Transpl 2007; 13 (Suppl 2):S79-S82.
177. Lucey MR. Liver transplantation for alcoholic liver disease. Clin Liver Dis 2007; 11:283-289.
178. Gaillimberti L, Forza G, Angeli P, et al. Alcohol- and substance-dependent subjects: the correlated factors in qualifying for liver transplantation. Transplant Proc 2007; 39:1861-1863.
179. Haber PS, McCaughan GW. 'I'll never touch it again, doctor!' - harmful drinking after liver transplantation. Hepatology 2007; 45:1302-1304.
180. Kotlyar DS, Burke A, Campbell MS, Weinrieb RM. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. Am J Gastroenterol 2007; 102:1-10.
181. Wells JT, Said A, Agni R, et al. The impact of acute alcoholic hepatitis in the explanted recipient liver on the outcome after liver transplantation. Liver Transplant 2007; 13:1728-1735.
182. Dumortier J, Guillaud O, Adham M, et al. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. Am J Gastroenterol 2007; 102:1032-1041.